Zerebrale Vaskulitis: ein Update zu Symptomen, Diagnostik und Therapie

Die primäre zerebrale Vaskulitis ist eine seltene Erkrankung. Ihre Diagnostik ist jedoch durch die Mannigfaltigkeit der klinischen Symptomatik und die häufig unspezifischen Befunde in den einzelnen Untersuchungsmethoden erschwert [1]. Dieser Beitrag fasst die klinische Symptomatik sowie die einzelnen diagnostischen Untersuchungsmethoden und Therapieoptionen zusammen.

• Literatur

• 1 Deb-Chatterji M, Schuster S, Haeussler V. et al. Primary Angiitis of the Central Nervous System: New Potential Imaging Techniques and Biomarkers in Blood and Cerebrospinal Fluid. Front Neurol 2019; 10: 568
• 2 Lucke M, Hajj-Ali RA. Advances in primary angiitis of the central nervous system. Curr Cardiol Rep 2014; 16: 533
• 3 Calabrese LH, Mallek JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria.. Medicine (Baltimore) 1988; 67: 20-39
• 4 Birnbaum J, Hellmann DB. Primary angiitis of the central nervous system. Arch Neurol 2009; 66: 704-709
• 5 Salvarani C, Brown Jr RD , Christianson TJH. et al. Long-term remission, relapses and maintenance therapy in adult primary central nervous system vasculitis: A single-center 35-year experience. Autoimmun Rev 2020;
• 6 Salvarani C, Brown Jr RD , Christianson T. et al. An update of the Mayo Clinic cohort of patients with adult primary central nervous system vasculitis: description of 163 patients. Medicine (Baltimore) 2015; 94: e738
• 7 Schmidley JW. 10 questions on central nervous system vasculitis. Neurologist 2008; 14: 138-139
• 8 Thom V, Schmid S, Gelderblom M. et al. IL-17 production by CSF lymphocytes as a biomarker for cerebral vasculitis. Neurol Neuroimmunol Neuroinflamm 2016; 3: e214
• 9 Deb M, Gerdes S, Heeren M. et al. Circulating endothelial cells as potential diagnostic biomarkers in primary central nervous system vasculitis. J Neurol Neurosurg Psychiatry 2013; 84: 732-734
• 10 Deb-Chatterji M, Pinnschmidt HO, Duan Y. et al. Circulating endothelial cells as promising biomarkers in the differential diagnosis of primary angiitis of the central nervous system. Front Neurol 2020; 11: 205
• 11 Zuccoli G, Pipitone N, Haldipur A. et al. Imaging findings in primary central nervous system vasculitis. Clin Exp Rheumatol 2011; 29: S104-109
• 12 de Boysson H, Zuber M, Naggara O. et al. Primary angiitis of the central nervous system: description of the first fifty-two adults enrolled in the French cohort of patients with primary vasculitis of the central nervous system. Arthritis Rheumatol 2014; 66: 1315-1326
• 13 Schuster S, Magnus T. Primäre Vaskulitis des Zentralnervensystems. Z Rheumatol 2015; 74: 854-856 , 858-860, 862
• 14 Salvarani C, Brown Jr RD , Calamia KT. et al. Angiographynegative primary central nervous system vasculitis: a syndrome involving small cerebral vessels. Medicine (Baltimore) 2008; 87: 264-271
• 15 Saam T, Habs M, Cyran CC. et al. Neue Aspekte der MRTBildgebung zur Diagnostik der Großgefäßvaskulitiden sowie der primären Angiitis des zentralen Nervensystems. Radiologe 2010; 50: 861-871
• 16 Noh HJ, Choi JW, Kim JP. et al. Role of high-resolution magnetic resonance imaging in the diagnosis of primary angiitis of the central nervous system. J Clin Neurol 2014; 10: 267-271
• 17 Lehman VT, Brinjikji W, Kallmes DF. et al. Clinical interpretation of high-resolution vessel wall MRI of intracranial arterial diseases. Br J Radiol 2016;
• 18 Parisi JE, Moore PM. The role of biopsy in vasculitis of the central nervous system. Semin Neurol 1994; 14: 341-348
• 19 Hajj-Ali RA, Calabrese LH. Primary angiitis of the central nervous system. Autoimmun Rev 2013; 12: 463-466
• 20 Singhal AB, Topcuoglu MA, Fok JW. et al. Reversible cerebral vasoconstriction syndromes and primary angiitis of the central nervous system: clinical, imaging, and angiographic comparison. Ann Neurol 2016; 79: 882-894
• 21 Singhal AB, Topcuoglu MA. Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome. Neurology 2017; 88: 228-236
• 22 Boitet R, de Gaalon S, Duflos C. et al. Long-term outcomes after reversible cerebral vasoconstriction syndrome. Stroke 2020; 51: 670-673
• 23 Berry JA, Cortez V, Toor H. et al. Moyamoya: An update and review. Cureus 2020; 12: e10994
• 24 Yang H, Zhang L, Wang M. et al. Clinical features of and risk factors for intracranial aneurysms associated with moyamoya disease. Int J Stroke 2020;
• 25 Guey S, Kraemer M, Herve D. et al. Rare RNF213 variants in the C-terminal region encompassing the RING-finger domain are associated with moyamoya angiopathy in Caucasians. Eur J Hum Genet 2017; 25: 995-1003
• 26 Locatelli M, Padovani A, Pezzini A. Pathophysiological mechanisms and potential therapeutic targets in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Front Pharmacol 2020; 11: 321
• 27 Mizuno T, Mizuta I, Watanabe-Hosomi A. et al. Clinical and genetic aspects of CADASIL. Front Aging Neurosci 2020; 12: 91
• 28 De Boysson H, Arquizan C, Guillevin L. et al. Rituximab for primary angiitis of the central nervous system: report of 2 patients from the French COVAC cohort and review of the literature. J Rheumatol 2013; 40: 2102-2103
• 29 Pagnoux C, de Boysson H. L38. How to treat primary vasculitis of the central nervous system. . Presse Med 2013; 42: 605-607
• 30 Salvarani C, Brown Jr RD, Calamia KT. et al. Rapidly progressive primary central nervous system vasculitis. Rheumatology (Oxford) 2011; 50: 349-358